181 related articles for article (PubMed ID: 21418033)
1. Antisense oligonucleotides for the treatment of dyslipidemia.
Gouni-Berthold I; Berthold HK
Curr Pharm Des; 2011; 17(9):950-60. PubMed ID: 21418033
[TBL] [Abstract][Full Text] [Related]
2. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
3. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
Dragan S; Serban MC; Banach M
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
[TBL] [Abstract][Full Text] [Related]
7. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
[TBL] [Abstract][Full Text] [Related]
8. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?
Sahebkar A; Watts GF
Cardiovasc Drugs Ther; 2013 Dec; 27(6):559-67. PubMed ID: 23913122
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
Lose JM; Dorsch MP; Bleske BE
Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
11. Understanding PCSK9 and anti-PCSK9 therapies.
McKenney JM
J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
Marais AD; Kim JB; Wasserman SM; Lambert G
Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
[TBL] [Abstract][Full Text] [Related]
13. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Shen L; Peng H; Xu D; Zhao S
Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
[TBL] [Abstract][Full Text] [Related]
14. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
Shimada YJ; Cannon CP
Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
[TBL] [Abstract][Full Text] [Related]
15. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.
Lee P; Hegele RA
Expert Opin Investig Drugs; 2013 Nov; 22(11):1411-23. PubMed ID: 23889692
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic agents for lowering low density lipoprotein cholesterol.
Joy TR
Pharmacol Ther; 2012 Jul; 135(1):31-43. PubMed ID: 22465160
[TBL] [Abstract][Full Text] [Related]
17. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 inhibition - a novel mechanism to treat lipid disorders?
Banach M; Rizzo M; Obradovic M; Montalto G; Rysz J; Mikhailidis DP; Isenovic ER
Curr Pharm Des; 2013; 19(21):3869-77. PubMed ID: 23286435
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein cholesterol lowering therapies: what is on the horizon?
Gadi R; Figueredo VM
J Cardiovasc Med (Hagerstown); 2015 Jan; 16(1):1-10. PubMed ID: 25379719
[TBL] [Abstract][Full Text] [Related]
20. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
Farnier M
Am J Cardiovasc Drugs; 2011 Jun; 11(3):145-52. PubMed ID: 21619378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
